Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry platform, transforming samples to insights.

新增 MOBILion 突破性的 SLIM 高分辨率离子淌度技术，该技术可在毫秒级时间内根据分子的大小、形状和电荷进行分离，与沃特世行业领先的质谱平台相辅相成，助力将样品转化为洞察。

Accelerates Waters' move into proteomics with research capabilities built for AI foundation and frontier models, pairing the unique speed and resolution of the Xevo™ MRT MS with data generation at the scale needed to power proteomics lab-in-the-loop research via Anthropic MCP and MHS protocol support..

加速沃特世进军蛋白质组学领域，其研究能力专为AI基础模型和前沿模型打造，将Xevo™ MRT质谱仪独特的速度与分辨率与大规模数据生成相结合，通过Anthropic MCP和MHS协议支持，赋能蛋白质组学“实验室闭环”研究。

Furthers Waters' ability to take proteomics downstream to clinical applications, creating long-term opportunity to translate protein biomarker discoveries into clinical validation, as well as large-scale, blood-based screening such as for MCED and MRD monitoring.

进一步提升沃特世将蛋白质组学技术向下游临床应用领域拓展的能力，从而创造长期机遇，推动蛋白质生物标志物的发现转化为临床验证，并实现大规模血液筛查，例如多癌早期检测（MCED）和分子残留病灶（MRD）监测。

MILFORD, Mass.

马萨诸塞州米尔福德

,

，

Nov. 3, 2026

2026年11月3日

/PRNewswire/ -- Waters Corporation (NYSE:

/美通社/ -- 沃特世公司（纽约证券交易所：

WAT

WAT

), a global life sciences and diagnostics leader, today announced that it has acquired MOBILion Systems, Inc., the pioneer of SLIM high-resolution ion mobility separation technology for complex molecular analysis. The acquisition broadens Waters' entry into the proteomics market, pairing SLIM's separation power with Waters' Xevo™ MRT MS speed and resolution enabling superior bottom-up analysis of complex proteomes versus LC-MS alone..

全球生命科学与诊断领域的领导者沃特世公司（Waters Corporation）今日宣布，已收购MOBILion Systems, Inc.，该公司是用于复杂分子分析的SLIM高分辨率离子淌度分离技术的先驱。此次收购扩大了沃特世在蛋白质组学市场的布局，将SLIM的分离能力与沃特世Xevo™ MRT质谱仪的速度和分辨率相结合，从而相比仅使用液相色谱-质谱联用技术（LC-MS），能够实现对复杂蛋白质组的更优自下而上分析。

'Today's acquisition gives Waters a unique advantage in proteomics that will define our leadership, first in research and, over time, in the clinic. MOBILion's team brings deep expertise in developing and advancing this technology,' said Dr. Udit Batra, President and Chief Executive Officer, Waters Corporation.

“此次收购使沃特世在蛋白质组学领域获得独特优势，这将奠定我们的领导地位：首先是在研究方面，随着时间的推移，在临床方面也将如此。MOBILion 团队带来了开发和推进这项技术的深厚专业知识。”沃特世公司总裁兼首席执行官乌迪特·巴特拉博士表示。

'Pairing SLIM ion mobility separation with the speed, resolution and sensitivity capabilities of our mass spectrometry portfolio will help scientists better understand complex biology and transform data into actionable insights. It will also enable data generation at the scale AI foundation and frontier models need, opening the door to revolutionizing proteomics with lab-in-the-loop workflows.'.

将SLIM离子淌度分离技术与我们质谱产品组合的速度、分辨率和灵敏度优势相结合，将帮助科学家更深入地理解复杂的生物学过程，并将数据转化为可操作的洞察。此外，它还能以人工智能基础模型和前沿模型所需的大规模生成数据，从而通过“实验室在环”工作流程彻底变革蛋白质组学研究。

Strategic Benefits of the Acquisition

收购的战略效益

This acquisition accelerates Waters' strategy to enter and drive innovation in the attractive proteomics market, where LCMS proteomics is a $2 billion Total Addressable Market (TAM), growing at a high single-digit rate.

此次收购加速了沃特世进入极具吸引力的蛋白质组学市场并推动其创新的战略，其中液相色谱-质谱（LCMS）蛋白质组学的总潜在市场规模（TAM）达20亿美元，并以较高的个位数速率增长。

1

1

It creates several benefits:

它带来了多项益处：

Greater proteome depth through enhanced separation

通过增强分离提高蛋白质组深度

: MOBILion's SLIM (Structures for Lossless Ion Manipulations) technology provides high-resolution ion mobility separation, resolving molecular differences that are difficult to distinguish by liquid chromatography and mass spectrometry alone. Combined with Waters' mass spectroscopy portfolio, SLIM technology is expected to increase proteome coverage, sensitivity and throughput for complex biological samples.

MOBILion 公司的 SLIM（无损离子操控结构）技术提供高分辨率离子迁移率分离，能够解析仅靠液相色谱和质谱难以区分的分子差异。SLIM 技术与沃特世（Waters）的质谱产品组合相结合，有望提高复杂生物样品的蛋白质组覆盖度、灵敏度和通量。

Waters' high-end proteomics instruments will drive insights enabling downstream translational studies..

沃特世的高端蛋白质组学仪器将提供深刻洞察，推动下游转化研究。

High-throughput proteomics for AI-enabled research

用于人工智能赋能研究的高通量蛋白质组学

: SLIM enabled technology will drive insights supporting large cohort studies and high-throughput generation of high-quality data required by foundation and frontier AI models. Through Waters AI Link, which brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, and Waters' participation in Anthropic's Model Hardware Standard (MHS) research program, these capabilities support lab-in-the-loop experimentation, in which AI agents help design experiments and autonomously direct instrument operation.

SLIM 赋能技术将推动洞察生成，支持大规模队列研究以及基础 AI 模型和前沿 AI 模型所需的高质量数据的高通量生成。通过 Waters AI Link（将 Anthropic 的模型上下文协议（MCP）引入 waters_connect™ 软件）以及 Waters 参与 Anthropic 的模型硬件标准（MHS）研究计划，这些能力支持“实验室在环”实验，即 AI 智能体协助设计实验并自主指导仪器操作。

The acquisition also brings MOBILion's team and deep ion mobility expertise to Waters..

此次收购也将 MOBILion 的团队及其在离子迁移率领域的深厚专业知识带入沃特世公司。

Future translation of discoveries into targeted assays

未来将发现转化为靶向检测方法

: Using the Xevo TQ Absolute XR tandem quadrupole Mass Spectrometer, which offers industry-leading sensitivity and robustness, the acquisition creates a path from biomarker discovery to targeted biomarker verification and validation in clinical trial cohorts on a single platform as workflows in the waters_connect Platform support method transfer from discovery into development..

使用提供行业领先灵敏度和稳健性的Xevo TQ Absolute XR串联四极杆质谱仪，数据采集在单一平台上构建了从生物标志物发现到临床试验队列中靶向生物标志物验证与确认的路径，因为waters_connect平台中的工作流程支持方法从发现阶段向开发阶段的转移。

Longer-term opportunity in blood-based diagnostics:

血液诊断领域的长期机遇：

Waters' installed base of mass spectrometers in clinical laboratories provides a foundation for translating validated protein biomarkers into routine, blood-based tests. Over time, this creates test menu expansion opportunity for multiplex diagnostic workflows, serving applications such as Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) monitoring..

沃特世在临床实验室中安装的质谱仪基础，为将经过验证的蛋白质生物标志物转化为常规血液检测奠定了基础。随着时间的推移，这为多重诊断工作流程创造了检测项目扩展的机会，服务于多癌种早期检测（MCED）和微小残留病灶（MRD）监测等应用。

'SLIM was built to see what other separations miss,' said Dr. Melissa Sherman, Chief Executive Officer, MOBILion Systems. 'Waters is the ideal home for this technology given its rich history of leadership in separation science and mass spectrometry. By bringing our high-resolution ion mobility technology together with Waters' complementary differentiated multi reflecting time of flight technology, we can extend the impact of SLIM and help scientists reveal more meaningful discoveries in proteomics, enabling it to progress from leading research labs into routine testing worldwide.'.

“SLIM 的构建旨在揭示其他分离技术所遗漏的信息，”MOBILion Systems 首席执行官 Melissa Sherman 博士表示。“鉴于沃特世公司在分离科学和质谱领域拥有悠久的领导历史，这里是这项技术的理想归宿。通过将我们的高分辨率离子淌度技术与沃特世互补且独具特色的多反射飞行时间技术相结合，我们可以扩大 SLIM 的影响力，帮助科学家在蛋白质组学领域取得更多有意义的发现，推动该技术从顶尖研究实验室走向全球范围内的常规检测。”

Financial terms of the transaction were not disclosed.

交易的财务条款未予披露。

1

1

Based on Waters internal analysis and estimates, incorporating consulting data, industry reports and market research.

基于沃特斯的内部分析与估算，并结合咨询数据、行业报告及市场研究。

About MOBILion

关于MOBILion

MOBILion is a scientific instrumentation company developing innovative ion mobility technologies that advance the separation and characterization of complex molecules. Its differentiated SLIM technology provides a new approach to high-resolution ion mobility separation, helping scientists gain deeper insights from complex samples..

MOBILion 是一家科学仪器公司，致力于开发创新的离子迁移技术，以推动复杂分子的分离与表征。其独特的 SLIM 技术为高分辨率离子迁移分离提供了新方法，帮助科学家从复杂样品中获得更深入的洞察。

About Waters Corporation

关于沃特世公司

Waters Corporation

沃特世公司

(NYSE:

（纽约证券交易所：

WAT

WAT

) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology.

）是全球生命科学与诊断领域的领导者，致力于通过分析技术、信息学和服务加速前沿科学成果的转化与应用。我们专注于受监管的高通量检测环境，凭借在化学、物理学和生物学领域的深厚科学专业知识，打造创新产品组合。

We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~15,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.

我们与全球客户携手合作，推动高效、高质量药物的上市，确保食品和饮用水安全，并通过早期疾病检测、常规感染管理以及应对抗生素耐药性，改善患者治疗结果。秉承不懈创新的共同文化，我们约15,000名充满热情的同事将科学挑战转化为突破，从而改善世界各地人们的生活。

For more information, please visit .

更多信息，请访问。

www.waters.com/about

www.waters.com/about

.

。

Waters, Xevo, waters_connect, MOBILion and SLIM are trademarks of Waters Corporation or its affiliates. Anthropic is a trademark of Anthropic, PBC. Model Context Protocol is a trademark of LF Projects, LLC.

Waters、Xevo、waters_connect、MOBILion 和 SLIM 是沃特世公司（Waters Corporation）或其关联公司的商标。Anthropic 是 Anthropic, PBC 的商标。Model Context Protocol 是 LF Projects, LLC 的商标。

Cautionary Statement

警示声明

This release contains 'forward-looking' statements regarding future results and events, including statements regarding the expected benefits of the transaction. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words 'will,' 'feels', 'believes', 'anticipates', 'plans', 'expects', 'intends', 'suggests', 'appears', 'estimates', 'projects' and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements.

本公告包含有关未来业绩和事件的“前瞻性”陈述，包括关于交易预期益处的陈述。为此，任何非历史事实的陈述均可被视为前瞻性陈述。在不限制前述内容的前提下，“将”、“感觉”、“相信”、“预计”、“计划”、“期望”、“打算”、“建议”、“似乎”、“估计”、“预测”等词语及其否定或肯定形式，均旨在识别前瞻性陈述。

Our actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks or uncertainties related to, and expectations regarding our ability to realize commercial success subsequent to the completion of our acquisition of the Business and other risk factors detailed from time to time in Waters' reports filed with the Securities and Exchange Commission ('SEC').

由于多种原因，我们的实际未来业绩可能与本新闻稿中前瞻性陈述所讨论的结果存在重大差异，包括但不限于与我们在完成业务收购后实现商业成功的能力相关的风险和不确定性，以及对此的预期，同时还包括Waters在向美国证券交易委员会（“SEC”）提交的报告中不时详述的其他风险因素。

Such factors and others that are discussed more fully in the sections entitled 'Forward-Looking Statements' and 'Risk Factors' of Waters' annual report on Form 10-K for the year ended December 31, 2025 as filed with the SEC, which discussions are incorporated by reference in this release, as updated by Waters' subsequent filings with the SEC.

此类因素以及在沃特士公司向美国证券交易委员会（SEC）提交的截至2025年12月31日年度的10-K表格年度报告中“前瞻性陈述”和“风险因素”章节更全面讨论的其他因素，该等讨论通过引用方式纳入本新闻稿，并已由沃特士公司随后向SEC提交的文件予以更新。

The forward-looking statements included in this release represent Waters' estimates or views as of the date of this release and should not be relied upon as representing Waters' estimates or views as of any date subsequent to the date of this release. Except as required by law, Waters does not assume any obligation to update any forward-looking statements..

本新闻稿中包含的前瞻性陈述代表沃特世公司截至本新闻稿发布之日的估计或观点，不应被视为代表沃特世公司在本新闻稿发布之日之后任何日期的估计或观点。除法律要求外，沃特世公司不承担任何更新任何前瞻性陈述的义务。

Contact:

联系方式：

Molly Gluck

莫莉·格拉克

Director, Product Communications

产品传播总监

Waters Corporation

沃特世公司

+1.508.498.9732

+1.508.498.9732

[email protected]

[email protected]

Caspar Tudor

卡斯帕·都铎

Head of Investor Relations

投资者关系负责人

Waters Corporation

沃特世公司

+1.508.482.3448

+1.508.482.3448

[email protected]

[email protected]

SOURCE Waters Corporation

来源：沃特世公司